Heat Shock Protein 90 (HSP90) Inhibitors as Anticancer Medicines: A Review on the Computer-Aided Drug Discovery Approaches over the Past Five Years

Table 2

HSP90 inhibitors in clinical evaluation [97].

Inhibitor	Company	Class	Route	Phase
Tanespimycin (17-AAG, KOS-953)	Kosan Biosciences/Bristol Myers Squibb	GA	IV	III
Alvespimycin (17-DMAG)	Kosan Biosciences/Bristol Myers Squibb	GA	IV; oral	I
Etaspimycin (IPI-504)	Infinity Pharmaceuticals	GA	IV	III
IPI-493	Infinity Pharmaceuticals	GA	Oral	I
CNF2024/BIIB 021	Biogen Idec	Purine	Oral	II
MPC-3100	Myriad Pharmaceuticals/Myrexis	Purine	Oral	I
Debio 0932 (CUDC-305)	Debiopharm	Purine-like	Oral	I
PU-H71	Samus Therapeutics	Purine	IV	I
Ganetespib (STA-9090)	Synta Pharmaceuticals	Resorcinol-triazole	IV	II
NVP-AUY922 (VER-52269)	Novartis	Resorcinol-isoxazole	IV	II
HSP990	Novartis	Not reported but claimed as a follow-up compound to NVP-AUY922	Oral	I
KW-2478	Kyowa Hakko Kirin Pharma	Resorcinol	IV	I
AT13387	Astex	Resorcinol	IV oral	I
SNX-5422	Serenex/Pfizer	Indazol-4-one	Oral	I
DS-2248	Daiichi Sankyo Inc.	Not reported	Oral	I
XL888	Exelixis	Not reported	Oral	I